Related Experiment Video
Updated: Jun 28, 2026

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
Published on: July 11, 2013
Guselkumab for Psoriasis in Patients With Active or Prior Malignancy: A Multicentre Retrospective Study
Francisco Javier Melgosa Ramos1,2, Sergio Santos Alarcón3, Almudena Mateu Puchades2
1Department of Dermatology, Hospital Lluís Alcanyís, Xàtiva, Valencia, Spain.
Guselkumab effectively treated psoriasis in patients with a history of cancer, showing sustained skin and joint symptom improvement. The interleukin-23 (IL-23) inhibitor demonstrated a favorable safety profile in this complex population.
Area of Science:
- Dermatology
- Oncology
- Immunology
Background:
- Psoriasis management in patients with malignancy is challenging.
- Interleukin-23 (IL-23) inhibitors offer a potential therapeutic avenue.
Purpose of the Study:
- To evaluate the safety and effectiveness of guselkumab in patients with moderate-to-severe psoriasis and a history of cancer.
- To assess clinical outcomes and oncologic safety in this complex patient group.
Main Methods:
- Multicentre, retrospective, real-world study.
- Inclusion of 30 patients with moderate-to-severe psoriasis, including 11 with active malignancy at baseline.
- 52-week follow-up period.
Main Results:
- Guselkumab demonstrated sustained improvement in skin and joint symptoms.
- No cases of cancer progression or recurrence were observed.
- Two new malignancies developed, but guselkumab was not discontinued.
Conclusions:
- Guselkumab is a safe and effective treatment option for psoriasis in patients with current or past malignancy.
- IL-23 inhibitors represent a viable therapeutic strategy for this challenging patient population.
More Related Videos
07:29Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
Published on: April 22, 2019
06:46Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
Published on: September 27, 2024
Related Concept Videos
Clinical Trials: Overview
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Chronic Pancreatitis II: Collaborative Care
Assessment:
Bioavailability Study Design: Healthy Subjects Versus Patients